Login to Your Account



FDA clears IND for first China-made biologic: Alphamab's KN035

By Shannon Ellis
Staff Writer

Wednesday, November 30, 2016

SHANGHAI – More than five years in the making, the FDA has granted Suzhou Alphamab Co. Ltd. clinical trial approval in the U.S. for KN035, an anti-PD-L1 single-domain agent discovered, developed and manufactured in China.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription